Corcept Investors with Losses Over $100K Can Lead Securities Fraud Lawsuit

Rosen Law Firm reminds Corcept Therapeutics shareholders of April 21 lead plaintiff deadline

Apr. 16, 2026 at 11:09pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a stack of financial documents, a calculator, and a gavel floating on a clean, monochromatic background, conceptually representing the abstract corporate strategy and legal proceedings at the heart of the Corcept Therapeutics securities fraud case.A minimalist still life captures the high-stakes legal battle over alleged securities fraud at Corcept Therapeutics.NYC Today

Rosen Law Firm, a global investor rights law firm, is reminding purchasers of Corcept Therapeutics Incorporated (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025 of the important April 21, 2026 lead plaintiff deadline in a securities fraud class action lawsuit against the company.

Why it matters

The lawsuit alleges that Corcept made false and misleading statements about the clinical trials supporting its New Drug Application for relacorilant, a treatment for hypercortisolism. Investors who purchased Corcept stock during this period and suffered losses over $100,000 may be eligible to serve as lead plaintiff in the class action.

The details

According to the lawsuit, Corcept represented that the key clinical trials for relacorilant provided "powerful support" for the New Drug Application (NDA) it submitted to the FDA. However, the lawsuit claims the FDA had repeatedly raised concerns about the adequacy of the clinical evidence, creating a material risk that the NDA would not be approved. When this information became public, investors allegedly suffered damages.

  • The class period is from October 31, 2024 to December 30, 2025.
  • The lead plaintiff deadline is April 21, 2026.

The players

Corcept Therapeutics Incorporated

A biopharmaceutical company that develops and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders.

Rosen Law Firm

A global investor rights law firm that concentrates its practice in securities class actions and shareholder derivative litigation.

Got photos? Submit your photos here. ›

What they’re saying

“We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition.”

— Laurence Rosen, Founding Partner, Rosen Law Firm

What’s next

Investors with losses over $100,000 who purchased Corcept stock during the class period have until April 21, 2026 to move the court to serve as lead plaintiff in the class action lawsuit.

The takeaway

This case highlights the importance of thorough due diligence when investing, as well as the need for strong legal representation for shareholders seeking to recover losses from alleged corporate misconduct and securities fraud.